Skip to content

Myxedema Coma Case Study

JSM Clin Case Rep 1(1): 1008.

Submitted: 28 October 2013; Accepted: 12 December 2013; Published: 16 December 2013

Case Report

Myxedematous Coma: A Case Report

Marcelo Rodrigues Bacci1*, Janaina Aparecida Boide Santos2, Flávia Tobaldini Russo1, Patrícia Zilda de Souza1, Bruna Maria Grosso Mascarenhas1, Leonardo Fernando Ferrari Nogueira2 and Fernando Luiz Affonso Fonseca1

1Department of General Practice- Faculdade de Medicina do ABC, Brazil
2Department of Cardiology- Faculdade de Medicina do ABC, Brazil

*Corresponding author: Marcelo Rodrigues Bacci, Department of General Practice- Faculdade de Medicina do ABC, Av.Príncipe de Gales n 821, ZIP:09060-650, Santo André , São Paulo, Brazil, Tel: +55 11 981937005; Fax: +55 11 43515902; Email: mrbacci@yahoo.com

Abstract

Introduction: Thyroid dysfunctions are highly prevalent diseases. Despite of its high prevalence the presentation is unusual nowadays because of oral hormone therapy widely used in insufficiency of the gland however hyperfunction states are common also. About 12% of the US population will develop some alteration of thryroid function in their lifetime. Among these diseases we highlight the presence of myxedema coma in a female patient.
Case presentation: A 58-year-old female patient with symptoms of drowsiness and loss of motor coordination. At admission in the emergency department, ventilatory assistance was required, and the patient presented progressive improvement after oral levothyroxine reposition. Differential diagnosis of the reduction of consciousness highlighted the presence of infection and stroke. They were not detected. The ultrasonographic analysis showed a diffuse and heterogeneous enlargement of thyroid.|
Conclusion: Despite the possibility of adrenal insufficiency, pan hypopituitarism, infection and even a tumour, the thyroid stimulating hormone and free thyroxin levels were determinant to make the diagnosis of myxedematous coma according the signs and symptoms of the patient´s entrance presentation. Myxedema coma is a syndrome that results from the intense reduction of the thyroid hormone synthesis.

Keywords: Myxedema coma; Thyroid insufficiency; Endocrine disorders; Levothyroxin

Introduction

Thyroid gland disorders are pathologies ordinarily found in the clinical practice. It is estimated that 5.9 to 11.7% of the population presents alterations in laboratory exams performed for the analysis of the thyroid function [1]. Hypothyroidism is the most frequent disorder, and when not properly treated it may generate relevant consequences such as the myxedema coma, also known as myxedema crisis.

Not very frequent, with an estimated number of 0.22 million cases/year, it occurs due to the acute suppression of thyroid hormone production. Cases of myxedema coma usually occur in women with a significant mortality rate (25-60%) even when they are under proper treatment [2,3].

Myxedematous coma is a syndrome that results from the intense reduction of the thyroid hormone synthesis. There are some triggering factors like exposition to low temperatures, infections, irregular performance of hormone replacement therapy in patients with hypothyroidism, adverse reactions of medications like amiodarone, lithium, anesthetics, hypnotics, sedatives or tranquilizers. This syndrome may also be triggered by the intake of raw foods that, when broken down by myrosinase, release substances that inhibit the absorption of iodine. The cooking process deactivates the enzyme, and thus it does not interfere with the production of thyroid hormones [2].

This case refers to a patient who reported not having previous thyroid disorders and presented with hypothyroidism with myxedema coma.

Case Presentation

A 58-year-old black patient from the southeastern region of Brazil was brought into the emergency department al. She was admitted owing to drowsiness that lasted for seven days, reduction of motor coordination and slight mental confusion. The patient were hypertensive, diabetic, obese and had atrial fibrillation. Her past surgical records a mastectomy due to breast cancer followed by radiotherapy and chemotherapy eight years before her admission.

She regularly takes metoprolol 25 mg/day, metformin 1700 mg/day, fluoxetine 20 mg/day and amiodarone 200 mg/day.

At admission in the emergency room her vital signs revealed a blood pressure of 130/90 mmHg, heart rate of 83 bpm, axillary temperature of 95° F and pulse oximetry of 95% with no supplementation of oxygen.

The patient presented with dry skin, generalized slight pitting edema and drowsiness without motor or sensory deficits. She obeyed verbal commands with a score in the Glasgow Coma Scale of 13 (2/5/6). Inspection and palpation of the cervical region was performed and no goiter or neck stiffness was found.

The initial laboratory evaluation revealed the absence of anemia and electrolyte disturbances, however there were reduced renal function with an urea level of 71 mg/dl and a serum creatinine of 2 mg/dl. This alterations might be due the dehydration presented at admission. Thyroid function was altered with thyroid-stimulating hormone (TSH) of 16.75 mU/L and free thyroxin (T4) of 0.59 ng/dl.

Her consciousness level worsened in the 10 hours that followed her admission and orotracheal intubation along with mechanical ventilation were made necessary.

The syndromic diagnosis for the decreased level of consciousness required the performance of a skull tomography so that the possibility of a stroke could be excluded. It is important to point out that the patient had undergone previous breast cancer treatment, and based on the presented case a central nervous system tumor could justify part of the symptoms. No tumor or stroke was found in the tomography. Spinal fluid analysis dismissed the hypothesis of meningitis as well sepsis with the previous laboratorial findings.

The acute thyroid insufficiency leading to coma could not be disregarded due to the combination of several factors like the female sex, the chronic use of amiodarone and the picture of acute drowsiness and motor discoordination.

Once the hypothesis of myxedema coma came up, supplementation with an attack dose of 200 mcg of levothyroxin was started, followed by maintenance of 75 mcg on daily basis, after the analysis of the thyroid stimulating hormone and free thyroxin levels. A daily supplementation with 300 mg of hydrocortisone was also administered prior to serum cortisol collection. After one day of mechanical ventilation and the onset of the empiric supplementation, the patient regained consciousness and was extubated.

There were no alterations in the levels of antimicrosomal and antiperoxidase antibodies with respective values of 17.9 (reference < 35) and 20 (reference < 40). Morning cortisol value was 25.3 mcg/dL with reference value of 5-25 mcg/dL.

The ultrasonographic analysis of the thyroid showed a diffuse heterogeneous appearance of the echotexture with acinar ectasia, and the conclusion was diffuse goiter.

Discussion

Hampton J in a recent series reported that about 12% of people will experience some issue with thyroid in their lifetime [5].

According to this finding, our patient evoluted with thyroid insufficiency aggravated by insufficient treatment and its complication like coma.

The most dangerous complication is related with opposite sides: hyperfunction, the so called "thyroid storm" which is characterized by an enormous release of thyroid hormone into the circulation with a violent response of the organs¹ and hypofunction, the myxedema coma.

In this case, there was no thyroid storm but the opposite because the lack of production of thyroid hormone . Among the clinical and laboratory alterations found in the myxedema crisis, the presence of xerodermia, hairy rarefaction, hoarseness, non-pitting peripheral edema, macroglossia and impairment of deep reflexes can be observed [4].

As part of the syndrome, the presence of hypothermia, decreased level of consciousness, amnesia, hallucinations and seizures, gastric and enteric atony with possible ileus, ascites and gastrointestinal bleeding may be observed. Among the hematologic disorders, normocytic and normochromic anemia, von Willebrand disease, reduction in factors V, VII, VIII, IX and X production, decrease of granulocytes and an increased risk of disseminated intravascular coagulation are usually reported [2,3].

Hormone replacement therapy must be conducted early so that the physiological levels of hormones may be reached as soon as possible.

Oral supplementation proved to be as effective as the intravenous route [2]. However, owing to the presence of gastric atony in many patients, oral therapy may be disadvantageous once there is a lower absorption of the drug in such cases. Whenever available, triiodothyronin replacement is more effective than T4 replacement and it leads to the improvement of clinical and neurological symptoms in approximately 24 hours [3,5].

On account of the increased risk of association with adrenal insufficiency in these patients, it is prudent to start the replacement of corticosteroids with hydrocortisone, 50-100 mg/day for 7 days and weaning after clinical and laboratory improvement [2].

Despite the fact the outcome of the reported case was favorable, the evolution of a myxedema coma patient is bad even with the proper and early treatment. Aggravating factors include advanced age, decreased level of consciousness, and high APACHE II and SOFA scores [2]. The most probable triggering cause in the current case was the progressive worsening of thyroid and the lack of proper hormone replacement.

In conclusion, thyroid function must be analysed routinely because the high prevalence of dysfunction. Myxedematous coma can be extremely dangerous when it´s not recognized promptly. Whenever available, iv triiodothyronine replacement is more effective than iv T4 replacement. Intravenous route must be the preferential option due to the lower risk of enteric absorption which is inherent to the syndrome.

References

Cite this article: Bacci MR, Boide Santos JA, Russo FB, de Souza PZ, Grosso Mascarenhas BM, et al. (2013) Myxedematous Coma: A Case Report. JSM Clin Case Rep 1(1): 1008.

Go to Top

1. Wartofsky L. Myxoedema coma. Endocrinology Metabolism Clinics of North America. 2006;35:687–698.[PubMed]

2. Rodríguez I, Fluiters E, Pérez-Méndez LF, Luna R, Páramo C, García-Mayor RV. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. Journal of Endocrinology. 2004;180(2):347–350.[PubMed]

3. Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. 1999;9(12):1167–1174.[PubMed]

4. Dutta P, Bhansali A, Masoodi S, Bhadada S, Sharma N, Rajput R. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Critical Care. 2008;12(1):p. R1.[PMC free article][PubMed]

5. Reinhardt W, Mann K. Incidence, clinical picture, and treatment of hypothyroid coma: results of a survey. Medizinische Klinik. 1997;92:521–524.[PubMed]

6. Report of a Committee of the Clinical Society of London to Investigate the Subject of Myxedema. Vol. 21. London, UK: Transactions Clinical Society; 1888.

7. Wall CR. Myxedema coma: diagnosis and treatment. American Family Physician. 2000;62(11):2485–2490.[PubMed]

8. Nicoloff JT, LoPresti JS. Myxedema coma: a form of decompensated hypothyroidism. Endocrinology and Metabolism Clinics of North America. 1993;22(2):279–290.[PubMed]

9. Galofré JC, García-Mayor RV. Densidad de incidencia del coma mixedematoso. Endocrinologia. 1997;44:103–104.

10. Chu M, Seltzer TF. Myxedema coma induced by ingestion of raw bok choy. New England Journal of Medicine. 2010;362(20):1945–1946.[PubMed]

11. Gardner DG. Endocrine emergencies. In: Gardner DG, Shoback D, editors. Greenspan’s Basic and Clinical Endocrinology. 8th edition. New York, NY, USA: McGraw-Hill; 2007.

12. Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. American Journal of Medicine. 1988;84(5):877–883.[PubMed]

13. Wilson WR, Bedell GN. The pulmonary abnormalities in myxedema. The Journal of Clinical Investigation. 1960;39:42–55.[PMC free article][PubMed]

14. Massumi RA, Winnacker JL. Severe depression of the respiratory center in myxedema. The American Journal of Medicine. 1964;36(6):876–882.[PubMed]

15. Derubertis FR, Jr., Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB. Impaired water excretion in myxedema. The American Journal of Medicine. 1971;51(1):41–53.[PubMed]

16. Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. American Journal of Medicine. 1978;64(4):613–621.[PubMed]

17. Chen YC, Cadnapaphornchai MA, Yang J, et al. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. American Journal of Physiology—Renal Physiology. 2005;289(4):F672–F678.[PubMed]

18. Weirsinga WM. Hypothyroidism and myxedema coma. In: Jameson JL, Legroot LJ, editors. Endocrinology Adult and Pediatric. 6th edition. Philadelphia, Pa, USA: Saunders; 2010.

19. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. 1993;87(5):1435–1441.[PubMed]

20. Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. American Journal of the Medical Sciences. 2006;331(3):154–156.[PubMed]

21. Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363(9411):793–803.[PubMed]

22. Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005;112(20):3122–3130.[PubMed]

23. Galetta F, Franzoni F, Fallahi P, et al. Changes in heart rate variability andQT dispersion in patients with overt hypothyroidism. European Journal of Endocrinology. 2008;158:85–90.[PubMed]

24. Galetta F, Franzoni F, Fallahi P, et al. Heart rate variability and QT dispersion in patients with subclinical hypothyroidism. Biomedicine and Pharmacotherapy. 2006;60(8):425–430.[PubMed]

25. Osborn LA, Skipper B, Arellano I, MacKerrow SD, Crawford MH. Results of resting and ambulatory electrocardiograms in patients with hypothyroidism and after return to euthyroid status. Heart Disease. 1999;1(1):8–11.[PubMed]

26. Das KC, Mukherjee M, Sarkar TK, et al. Erythropoiesis and erythropoietin in hypo- and hyperthyroidism. Journal of Clinical Endocrinology and Metabolism. 1975;40(2):211–220.[PubMed]

27. Hines JD, Halsted CH, Griggs RC, Harris JW. Megaloblastic anemia secondary to folate deficiency associated with hypothyroidism. Annals of Internal Medicine. 1968;68(4):792–805.[PubMed]

28. Carmel R, Spencer CA. Clinical and subclinical thyroid disorders associated with pernicious anemia. Archives of Internal Medicine. 1982;142(8):1465–1469.[PubMed]

29. Tudhope GR, Wilson GM. Deficiency of vitamin b12 in hypothyroidism. The Lancet. 1962;279(7232):703–706.[PubMed]

30. Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgraduate Medical Journal. 1990;66(774):280–284.[PMC free article][PubMed]

31. Michiels JJ, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clinical and Applied Thrombosis/Hemostasis. 2001;7(2):113–115.[PubMed]

32. Nitu-Whalley IC, Lee CA. Acquired von Willebrand syndrome—report of 10 cases and review of the literature. Haemophilia. 1999;5(5):318–326.[PubMed]

33. Erfurth EM, Ericsson UB, Egervallah K, Lethagen SR. Effect of acute desmopressin and of long-term thyroxine replacement onhaemostasis in hypothyroidism. Clinical Endocrinology. 1995;42:373–378.[PubMed]

34. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the euthyroid sick syndrome. Endocrine Reviews. 1982;3(2):164–217.[PubMed]

35. Hooper MJ. Diminished T.S.H. secretion during acute non thyroidal illness in untreated primary hypothyroidism. Lancet. 1976;1(7949):48–49.[PubMed]

36. Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet. 1966;2(7462):512–514.[PubMed]

37. Pozo-Rosich P, Villoslada P, Canton A, Simo R, Rovira A, Montalban X. Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. Journal of Neurology. 2002;249(8):1063–1065.[PubMed]

38. Canton A, de Fabregas O, Tintore M, et al. Encephalopathy associated to autoimmune thyroid disease: a more appropriate termfor an underestimated condition? Journal of the Neurological Sciences. 2000;176:65–69.[PubMed]

39. Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto’s encephalopathy years before onset of thyroid disease. European Neurology. 1999;41(2):79–84.[PubMed]

40. Yamamoto T. Delayed respiratory failure during the treatment of myxedema coma. Endocrinologia Japonica. 1984;31(6):769–775.[PubMed]

41. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. American Journal of Medicine. 2007;120(11):S1–S21.[PubMed]

42. Pereira VG, Haron ES, Lima Neto N, Medeiros Nets GA. Management of myxedema coma: report on three successfully treated cases with nasogastric or intravenous administration of triiodothyronine. Journal of Endocrinological Investigation. 1982;5(5):331–334.[PubMed]

43. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. Journal of the American Society of Nephrology. 1994;4(8):1522–1530.[PubMed]

44. Brunner JE, Redmond JM, Haggar AM, Kruger DF, Elias SB. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Annals of Neurology. 1990;27(1):61–66.[PubMed]

45. Holvey DN, Goodner CJ, Nicoloff JT, Dowling JT. Treatment of myxedema coma with intravenous thyroxine. Archives of Internal Medicine. 1964;113:89–96.[PubMed]

46. Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine. Annals of Internal Medicine. 1972;77(4):549–555.[PubMed]

47. MacKerrow SD, Osborn LA, Levy H, Eaton RP, Economou P. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Annals of Internal Medicine. 1992;117(12):1014–1015.[PubMed]

48. Hylander B, Rosenqvist U. Treatment of myxoedema coma—factors associated with fatal outcome. Acta Endocrinologica. 1985;108(1):65–71.[PubMed]